XTSE:VRX Valeant Pharmaceuticals International Inc Insider Activity 4 Filing - 6/4/2012

Effective Date 6/4/2012

XTSE:VRX Fair Value Estimate
Premium
XTSE:VRX Consider Buying
Premium
XTSE:VRX Consider Selling
Premium
XTSE:VRX Fair Value Uncertainty
Premium
XTSE:VRX Economic Moat
Premium
XTSE:VRX Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ValueAct Holdings, L.P.
  2. Issuer Name and Ticker or Trading Symbol
Valeant Pharmaceuticals International, Inc. [VRX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
See Remarks
(Last)
(First)
(Middle)
435 PACIFIC AVENUE, 4TH FLOOR, 
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2012
(Street)

SAN FRANCISCO, CA 94133
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, no par value 06/04/2012   A   8,062(1) A $ 0 81,106(2) I See footnotes(3)(4)
Common Stock, no par value               17,506,495 I See footnotes(3)(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ValueAct Holdings, L.P.
435 PACIFIC AVENUE, 4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks
ValueAct Capital Master Fund, L.P.
435 PACIFIC AVENUE
4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks
VA Partners I, LLC
435 PACIFIC AVENUE, 4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks
ValueAct Capital Management, L.P.
435 PACIFIC AVENUE, 4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks
ValueAct Capital Management, LLC
435 PACIFIC AVENUE, 4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks
ValueAct Holdings GP, LLC
435 PACIFIC AVENUE, 4TH FLOOR
SAN FRANCISCO, CA 94133
  X     See Remarks

Signatures

 VALUEACT HOLDINGS, L.P., By: VALUEACT HOLDINGS GP, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

 VALUEACT CAPITAL MASTER FUND, L.P., By: VA PARTNERS I, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

 VA PARTNERS I, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

 VALUEACT CAPITAL MANAGEMENT, L.P., By: VALUEACT CAPITAL MANAGEMENT, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

 VALUEACT CAPITAL MANAGEMENT, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

 VALUEACT HOLDINGS GP, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer   06/06/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Annual grant of Restricted Share Units (RSUs) to G. Mason Morfit, a member of the Board of Directors of the Issuer.
(2) This number represents common stock and other equity awards to G. Mason Morfit, a member of the Board of Directors of the Issuer, that were previously reported in Table 1.
(3) Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(4) Under an agreement with ValueAct Capital, G. Mason Morfit is deemed to hold the restricted share units for the benefit of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
(5) The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
 
Remarks:
-The reporting persons herein may be deemed to be members of a "group" for purposes of the Securities Exchange Act of 1934, as amended. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by such reporting person. This report shall not be deemed an admission that such reporting person is a member of a group or the beneficial owner of any securities not directly owned by such reporting person.

-G. Mason Morfit, a member of the management board of ValueAct Holdings GP, LLC, serves on the board of directors of the Issuer. As a result, the reporting persons herein may be deemed directors by deputization.

Joint Filer Information:  

Name: ValueAct Capital Master Fund, L.P.
Address: 435 Pacific Ave, 4th Fl, San Francisco, CA 94133
Designated Filer: ValueAct Holdings, L.P. 
Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX)
Date of Event Requiring Statement: 06/04/2012

Name: VA Partners I, LLC
Address: 435 Pacific Ave, 4th Fl, San Francisco, CA 94133
Designated Filer: ValueAct Holdings, L.P.
Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX)
Date of Event Requiring Statement: 06/04/2012

Name: ValueAct Capital Management, L.P.
Address: 435 Pacific Ave, 4th Fl, San Francisco, CA 94133
Designated Filer: ValueAct Holdings, L.P.
Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX)
Date of Event Requiring Statement: 06/04/2012

Name: ValueAct Capital Management, LLC
Address: 435 Pacific Ave, 4th Fl, San Francisco, CA 94133
Designated Filer: ValueAct Holdings, L.P. 
Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX)
Date of Event Requiring Statement: 06/04/2012

Name: ValueAct Holdings GP, LLC
Address: 435 Pacific Ave, 4th Fl, San Francisco, CA 94133
Designated Filer: ValueAct Holdings, L.P. 
Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX)
Date of Event Requiring Statement: 06/04/2012

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XTSE:VRX Valeant Pharmaceuticals International Inc Insider Activity 4 Filling

Valeant Pharmaceuticals International Inc XTSE:VRX Stock - Get Insider Activity SEC Filing of Valeant Pharmaceuticals International Inc XTSE:VRX stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XTSE:VRX Valeant Pharmaceuticals International Inc Insider Activity 4 Filing - 6/4/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XTSE:VRX Valeant Pharmaceuticals International Inc Insider Activity 4 Filing - 6/4/2012  |  Next: XTSE:VRX Valeant Pharmaceuticals International Inc Insider Activity 4 Filing - 6/5/2012